In the Matter of Impax Laboratories Inc.Date Filed: January 23, 2017
District Court: Federal Trade Commission – Docket No. 9373
Nature of Suit: Generic Competition Block or Delay|Antitrust
Defendant Type: Pharma
Plaintiff Type: Federal
Case Info: https://www.ftc.gov/enforcement/cases-proceedings/141-0004/impax-laboratories-inc
Court Document: https://www.ftc.gov/system/files/documents/cases/docket_no_9373_impax_part_3_administrative_complaint_redacted_public_version_1-23-17.pdf; https://www.ftc.gov/system/files/documents/cases/d09373initialdecisionpublic.pdf
The Federal Trade Commission sued generic drugmaker Impax Laboratories Inc. for allegedly accepting more than $100 million to delay its release of a generic version of Endo Pharmaceuticals Inc.’s opioid pain medication, Opana ER. An ALJ dismissed FTC complaint saying the magnitude of anticompetitive harm was outweighed by procompetitive benefits. The FTC has filed an appeal to the full commission.